Immuneering Corporation Profile Avatar - Palmy Investing

Immuneering Corporation

Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorect…

Biotechnology
US, Cambridge [HQ]
Growth Rates · Payout · Yield

Dividends Over Time

  • Records
  • Forecasts [Soon]
Growth Rates
% YoY
% 3Yr
% 5Yr
% 10Yr
Key Metrics
- -% TTM Yield
- - Average Days Gap
Series
% - - Yield
0.00% Payout Ratio
Cash Amount Pay Date
Cash Amount Pay Date
End of IMRX's Analysis
CIK: 1790340 CUSIP: 45254E107 ISIN: US45254E1073 LEI: - UEI: -
Secondary Listings
IMRX has no secondary listings inside our databases.